School of Medicine
Showing 331-340 of 1,546 Results
-
Kara Davis
Associate Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsChildhood cancers can be considered aberrations of normal tissue development. We are interested in understanding childhood cancers through the lens of normal development. Further, individual tumors are composed of heterogeneous cell populations, not all cells being equal in their ability to respond to treatment or to repopulate a tumor. Thus, we take single cell approach to determine populations of clinical relevance.
-
John W. Day, MD, PhD
Professor of Neurology and Neurological Sciences (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
On Partial Leave from 02/15/2026 To 10/18/2026Current Research and Scholarly InterestsOur Neuromuscular Division coordinates a comprehensive effort to conquer peripheral nerve and muscle disorders, including the muscular dystrophies, motor neuron disorders, neuromuscular junction abnormalities, and peripheral neuropathies. With patients and families foremost in mind, we have had success defining and combating these diseases, with research focused on identifying genetic causes, developing novel treatment, and maximizing patient function by optimizing current management.
-
Cornelia L. Dekker, M.D.
Professor (Research) of Pediatrics (Infectious Diseases), Emerita
Current Research and Scholarly InterestsThe Stanford-LPCH Vaccine Program provides an infrastructure for conducting clinical studies of vaccines in children and adults. We conduct immunology studies of seasonal influenza vaccines in twins, in a longitudinal cohort of young and elderly adults and studies of various vaccine candidates for NIH and industry. Additionally, we were a CDC Clinical Immunization Safety Assessment site for 10 years working on safety issues concerning licensed vaccines.
-
Claudia Del Toro Runzer
Postdoctoral Scholar, Medical Genetics
BioClaudia Del Toro Runzer is a postdoctoral scholar at Stanford University specializing in gene therapy and regenerative medicine. Her current research focuses on developing gene editing strategies for inherited disorders, including GNE myopathy and Gaucher disease. She works on advancing precision gene engineering approaches in human hematopoietic stem and progenitor cells and other clinically relevant cell types, with the goal of enabling safe and durable therapeutic correction.
Dr. Del Toro Runzer earned her PhD in Tissue Engineering from the MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University. Her doctoral research focused on chemically modified mRNA therapeutics for bone regeneration, where she investigated molecular design, intracellular trafficking, and biomaterial-assisted delivery systems to enhance protein expression and osteogenic outcomes. Her work resulted in multiple first-author publications in leading journals, including Advanced Functional Materials, Bone Research, Materials Today, and Molecular Therapy: Nucleic Acids.
Prior to her PhD, she completed an M.Sc. in Regenerative Biology and Medicine at Technische Universität Dresden and a B.Sc. in Biotechnology Engineering at Instituto Tecnológico de Monterrey. Her international training spans Germany, the Netherlands, Mexico, and the United States, with research experience in organoid systems, tissue regeneration, biomaterials engineering, and microphysiological platforms.
